Chengda Bio released its 2026 interim report, with net profit attributable to the parent company of 33.28 million yuan, a decrease of 72.79% compared with the same period last year. The company's total operating revenue was 677 million yuan, a year-on-year decrease of 4.18%; net cash inflow from operating activities was 70.76 million yuan, down 44.05% year-on-year. The company's latest gross margin was 74.24%, a decrease of 4.86 percentage points from the same period last year; diluted earnings per share was 0.08 yuan, down 73.33% year-on-year.
Liaoning Chengda Biotechnology Co. Ltd. ANet profit down 72.79% year-on-year, with revenue and cash flow also declining.
